<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">cardiovascular</journal-id><journal-title-group><journal-title xml:lang="ru">Кардиоваскулярная терапия и профилактика</journal-title><trans-title-group xml:lang="en"><trans-title>Cardiovascular Therapy and Prevention</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1728-8800</issn><issn pub-type="epub">2619-0125</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15829/1728-8800-2021-3060</article-id><article-id custom-type="elpub" pub-id-type="custom">cardiovascular-3060</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ИССЛЕДОВАНИЯ, МЕТААНАЛИЗЫ, РЕГИСТРЫ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>RESEARCH, META-ANALYSES, REGISTERS</subject></subj-group></article-categories><title-group><article-title>Расширенная клинико-инструментальная шкала прогнозирования риска смерти и нефатальных сердечно-сосудистых осложнений у больных регистра ПРОГНОЗ ИБС</article-title><trans-title-group xml:lang="en"><trans-title>Enhanced risk stratification scale for predicting death and non-fatal cardiovascular events in patients of the PROGNOZ IBS registry</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0160-0158</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Толпыгина</surname><given-names>С. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Tolpygina</surname><given-names>S. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Толпыгина Светлана Николаевна  — доктор медицинских наук, ведущий научный сотрудник отдела профилактической фармакотерапии</p><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><email xlink:type="simple">stolpygina@gnicpm.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7717-4362</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Марцевич</surname><given-names>С. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Martsevich</surname><given-names>S. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Марцевич Сергей Юрьевич  — доктор медицинских наук, профессор, главный научный сотрудник и  руководитель отдела профилактической фармакотерапии</p><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><email xlink:type="simple">smartsevich@gnicpm.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1493-4544</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Деев</surname><given-names>А. Д.</given-names></name><name name-style="western" xml:lang="en"><surname>Deev</surname><given-names>A. D.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Деев Александр Дмитриевич — кандидат физико-математических наук, руководитель лаборатории биостатистики</p><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><email xlink:type="simple">adeev@gnicpm.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБУ “Национальный медицинский исследовательский центр терапии и профилактической медицины” Минздрава России</institution></aff><aff xml:lang="en"><institution>National Medical Research Center for Therapy and Preventive Medicine</institution></aff></aff-alternatives><pub-date pub-type="collection"><year>2021</year></pub-date><pub-date pub-type="epub"><day>17</day><month>11</month><year>2021</year></pub-date><volume>20</volume><issue>7</issue><fpage>3060</fpage><lpage>3060</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Толпыгина С.Н., Марцевич С.Ю., Деев А.Д., 2021</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="ru">Толпыгина С.Н., Марцевич С.Ю., Деев А.Д.</copyright-holder><copyright-holder xml:lang="en">Tolpygina S.N., Martsevich S.Y., Deev A.D.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://cardiovascular.elpub.ru/jour/article/view/3060">https://cardiovascular.elpub.ru/jour/article/view/3060</self-uri><abstract><sec><title>Цель</title><p>Цель. Разработать шкалу стратификации риска сердечно-сосудистых осложнений у  больных хронической ишемической болезнью сердца (ИБС) на основе данных регистра ПРОГНОЗ ИБС.</p></sec><sec><title>Материал и  методы</title><p>Материал и  методы. В  регистр ПРОГНОЗ ИБС был включен 641 пациент (500 мужчин и  141 женщина), проживающие в  Москве и  Московской области, в  плановом порядке последовательно поступавшие в  стационар ФГБУ “ГНИЦ ПМ” Минздрава России с 01.01.2004 по 31.12.2007гг с предварительным диагнозом ИБС, которым во время госпитализации была выполнена коронароангиография. Диагноз ИБС был подтвержден у 84% больных. Жизненный статус установлен у 551 (86%) больных в 2010г и 583 (92%) в 2014г. Длительность наблюдения составила 7 лет. Проведен многомерный статистический анализ прогностической значимости данных, полученных при первичной госпитализации.</p></sec><sec><title>Результаты</title><p>Результаты. В  расширенную клинико-инструментальную шкалу вошли факторы с  наибольшей прогностической значимостью в  отношении вероятности развития сердечно-сосудистых осложнений (ССО). Наличие хронической сердечной недостаточности III-IV функционального класса (по NYHA) повышало относительный риск ССО в 5,4 раза (3 балла), атеросклеротического аортального стеноза в 2,8 раза (2 балла), перенесенного инсульта в 2,3 раза (3 балла), подтвержденный диагноз ИБС в  1,7 раз (1 балл), наличие жалоб на одышку в 1,4 раза (1 балл), признаки нестабильности течения ИБС в последние 3 мес. в 1,4 раза (1 балл), прием диуретиков до госпитализации в 1,9 раз (1 балл), фракция выброса левого желудочка 40-60% и диастолическая дисфункция левого желудочка при эхокардиографии в  1,9 и  2 раза (по 1 баллу), соответственно, увеличение частоты сердечных сокращений на электрокардиограмме покоя &gt;90 уд./мин в 1,7 раз (1 балл), наличие хронической болезни легких или почечной недостаточности в  1,5 раз (1 балл). Риск фатальных и нефатальных ССО у пациентов с ИБС в течение 7 лет считают низким при сумме баллов шкалы 0-3, при 4-5 баллах — средним с увеличением риска ССО в 3 раза, при индексе ≥6 баллов — высоким с увеличением риска в 9 раз.</p></sec><sec><title>Заключение</title><p>Заключение. Расширенная клинико-инструментальная шкала позволяет прогнозировать риск развития фатальных и  нефатальных ССО у пациентов с предполагаемой и подтвержденной ИБС и пригодна для широкого использования за счет своей информативности, простоты и доступности.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Aim</title><p>Aim. To develop a risk stratification scale for predicting cardiovascular events (CVEs) in patients with chronic coronary artery disease (CAD) based on the data from the PROGNOZ IBS registry.</p></sec><sec><title>Material and methods</title><p>Material and methods. The PROGNOZ IBS registry included 641 patients (men, 500; women, 141) living in Moscow and the Moscow Region, who were routinely admitted to the National Medical Research Center for Therapy and Preventive Medicine from January 1, 2004 to December 31, 2007 with a preliminary diagnosis of CAD. All included participants underwent coronary angiography during hospitalization. The diagnosis of CAD was verified in 84% of patients. The vital status was established in 551 (86%) patients in 2010 and 583 (92%) in 2014. The follow-up period was 7 years. A multivariate statistical analysis of the predictive value of data obtained during primary hospitalization was carried out.</p></sec><sec><title>Results</title><p>Results. The enhanced risk stratification scale included factors with the highest predictive value for developing CVEs. The presence of NYHA class III-IV heart failure increased the relative risk of CVEs by 5,4 times (3 points), atherosclerotic aortic stenosis by 2,8 times (2 points), stroke by 2,3 times (3 points), a confirmed diagnosis of CAD by 1,7 times (1  point), the presence of dyspnea by 1,4 times (1 point), unstable CAD course in the last 3 months by 1,4 times (1 point), taking diuretics before hospitalization by 1,9 times (1 point), left ventricular ejection fraction of 40-60% and left ventricular diastolic dysfunction according to echocardiography by 1,9 and 2 times (1 point each), respectively, an increase in the heart rate according resting electrocardiography &gt;90 bpm by 1,7 times (1 point), the presence of chronic lung disease or renal failure by 1,5 times (1 point). Seven-year risk of fatal and nonfatal CVEs in patients with CAD in case of score of 0-3 is considered low, score of 4-5 points — moderate (increase in CVE risk by 3 times), score of ≥6 — high (increase in CVE risk by 9 times).</p></sec><sec><title>Conclusion</title><p>Conclusion. The enhanced risk stratification scale allows predicting the risk of fatal and non-fatal CVC in patients with suspected and confirmed CAD and may be used for widespread use due to informative value, simplicity and availability.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>хроническая ишемическая болезнь сердца</kwd><kwd>прогноз</kwd><kwd>регистр</kwd><kwd>стратификация риска</kwd><kwd>сердечно-сосудистые осложнения</kwd><kwd>прогностическая шкала</kwd></kwd-group><kwd-group xml:lang="en"><kwd>chronic coronary artery disease</kwd><kwd>prognosis</kwd><kwd>register</kwd><kwd>risk stratification</kwd><kwd>cardiovascular events</kwd><kwd>prognostic scal</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Демографические итоги I полугодия 2018 года в России. Часть II. Демоскоп Weekly 2018;781-2. http://www.demoscope.ru/weekly/2018/0781/barom03.php.</mixed-citation><mixed-citation xml:lang="en">Demographic results of the first half of 2018 in Russia. Part II. Demoskop Weekly 2018;781-2. (In Russ.) http://www.demoscope.ru/weekly/2018/0781/barom03.php.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Тask Force Members, Montalescot G, Sechtem U, Achenbach S, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013;34(38):2949-3003. doi:10.1093/eurheartj/eht296.</mixed-citation><mixed-citation xml:lang="en">Тask Force Members, Montalescot G, Sechtem U, Achenbach S, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013;34(38):2949-3003. doi:10.1093/eurheartj/eht296.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Benjamin EJ, Muntner P, Alonso A, et al. Heart Disease and Stroke Statistics–2019 Update: A Report from the American Heart Association. Circulation. 2019;139(10):е56-528. doi:10.1161/CIR.0000000000000659.</mixed-citation><mixed-citation xml:lang="en">Benjamin EJ, Muntner P, Alonso A, et al. Heart Disease and Stroke Statistics–2019 Update: A Report from the American Heart Association. Circulation. 2019;139(10):е56-528. doi:10.1161/CIR.0000000000000659.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Perk J, De Backer G, Gohlke H, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 2012;33(13):1635-701. doi:10.1093/eurheartj/ehs092.</mixed-citation><mixed-citation xml:lang="en">Perk J, De Backer G, Gohlke H, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 2012;33(13):1635-701. doi:10.1093/eurheartj/ehs092.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Shaw LJ, Peterson ED, Shaw LK, et al. Use of a prognostic treadmill score in identifying diagnostic coronary disease subgroups. Circulation. 1998;98(16):1622-30. doi:10.1161/01.cir.98.16.1622.</mixed-citation><mixed-citation xml:lang="en">Shaw LJ, Peterson ED, Shaw LK, et al. Use of a prognostic treadmill score in identifying diagnostic coronary disease subgroups. Circulation. 1998;98(16):1622-30. doi:10.1161/01.cir.98.16.1622.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Малышева А.М., Марцевич С.Ю. Подходы к оценке риска сердечно-сосудистых осложнений у больных стабильной ишемической болезнью сердца. Профилактическая медицина. 2011;6:17-25.</mixed-citation><mixed-citation xml:lang="en">Malysheva AM, Martsevich SYu. Approaches to an assessment of risk of cardiovascular complications at patients with stable coronary heart disease. Preventive Medicine. 2011;6:17-25. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Fearon WF, Gauri AJ, Myers J, et al. A comparison of treadmill scores to diagnose coronary artery disease. Clin Cardiol. 2002;25(3):117-22. doi:10.1002/clc.4960250307.</mixed-citation><mixed-citation xml:lang="en">Fearon WF, Gauri AJ, Myers J, et al. A comparison of treadmill scores to diagnose coronary artery disease. Clin Cardiol. 2002;25(3):117-22. doi:10.1002/clc.4960250307.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Clayton TC, Lubsen J, Pocock SJ, et al. Risk score for predicting death, myocardial infarction, and stroke in patients with stable angina, based on a large randomized trial cohort of patients. BMJ. 2005;(331)7521:869. doi:10.1136/bmj.38603.656076.63.</mixed-citation><mixed-citation xml:lang="en">Clayton TC, Lubsen J, Pocock SJ, et al. Risk score for predicting death, myocardial infarction, and stroke in patients with stable angina, based on a large randomized trial cohort of patients. BMJ. 2005;(331)7521:869. doi:10.1136/bmj.38603.656076.63.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Daly CA, De Stavola B, Sendon JL, et al. Predicting prognosis in stable angina — results from the Euro heart survey of stable angina: prospective observational study. BMJ. 2006;(332)7536:262-7. doi:10.1136/bmj.38695.605440.ae.</mixed-citation><mixed-citation xml:lang="en">Daly CA, De Stavola B, Sendon JL, et al. Predicting prognosis in stable angina — results from the Euro heart survey of stable angina: prospective observational study. BMJ. 2006;(332)7536:262-7. doi:10.1136/bmj.38695.605440.ae.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Лупанов В. П., Чотчаев Х. Х., Евстифеева С. Е. и др. Клиническое течение заболевания и прогноз у больных ишемической болезнью сердца со стабильной стенокардией, обусловленной стенозирующим коронарным атеросклерозом (данные 20-летнего наблюдения). Терапевтический архив. 2002;9(74):13-20.</mixed-citation><mixed-citation xml:lang="en">Lupanov VP, Chotgaev HH, Evstifeyeva SE, et al. The clinical course of disease and prognosis in patients with coronary heart disease and stable angina due to stenotic coronary atherosclerosis (data from the 20-year follow-up). Therapeutic Archive. 2002;9(74):13-20. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Позднякова Н.В., Татарченко И. П., Соловьева К.В. Инструментальная оценка факторов риска в прогнозе кардиальных событий при ишемической болезни сердца. Функциональная диагностика. 2010;3:19-22.</mixed-citation><mixed-citation xml:lang="en">Pozdniakov NV, Tatarchenko IP, Soloviev KV. Instrumental assessment of risk factors in the prediction of cardiac events in ischemic heart disease. Functional Diagnostics. 2010;3:19-22. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Комаров А. Л., Илющенко Т. А., Шахматова О. О. и др. Сравнение эффективности консервативного и инвазивного лечения больных стабильной ИБС (по результатам пятилетнего проспективного наблюдения). Кардиология. 2012;52(8):4-14.</mixed-citation><mixed-citation xml:lang="en">Komarov AL, Ilyushchenko TA, Shakhmatova OO, et al. Comparative Efficacy of Conservative and Invasive Treatment of Patients with Stable Form of Ischemic Heart Disease (According to Results of Five Year Prospective Study). Kardiologiia. 2012;52(8):4-14. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Sachdev M, Sun JL, Tsiatis AA, et al. The prognostic importance of comorbidity for mortality in patients with stable coronary artery disease. J Am Coll Cardiol. 2004;4(43):576-82. doi:10.1016/j.jacc.2003.10.031.</mixed-citation><mixed-citation xml:lang="en">Sachdev M, Sun JL, Tsiatis AA, et al. The prognostic importance of comorbidity for mortality in patients with stable coronary artery disease. J Am Coll Cardiol. 2004;4(43):576-82. doi:10.1016/j.jacc.2003.10.031.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Wilson PWF, D’Agostino RSr, Bhatt DL, et al. An international model to predict recurrent cardiovascular disease. Am J Med. 2012;125(7):695-703. doi:10.1016/j.amjmed.2012.01.014.</mixed-citation><mixed-citation xml:lang="en">Wilson PWF, D’Agostino RSr, Bhatt DL, et al. An international model to predict recurrent cardiovascular disease. Am J Med. 2012;125(7):695-703. doi:10.1016/j.amjmed.2012.01.014.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Толпыгина С. Н., Марцевич С.Ю., Гофман Е.А. и др. Новая шкала прогнозирования риска смерти и нефатальных сердечно-сосудистых осложнений у больных из регистра “прогноз ИБС” в отдаленном периоде. Кардиология. 2016;6(56):12-7. doi:10.18565/cardio.2016.6.12-17.</mixed-citation><mixed-citation xml:lang="en">Tolpygina SN, Martsevich SY, Gofman EA, et al. Novel Scale for Long-Term Prognostication of Risk of Death and Nonfatal Cardiovascular Complications in Patients From the PROGNOSISIHD Registry. Kardiologiia. 2016;6(56):12-7. (In Russ.) doi:10.18565/cardio.2016.6.12-17.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Rapsomaniki E, Shah A, Perel P, et al. Prognostic models for stable coronary artery disease based on electronic health record cohort of 102 023 patients. Eur Heart J. 2014;35(13):844-52. doi:10.1093/eurheartj/eht533.</mixed-citation><mixed-citation xml:lang="en">Rapsomaniki E, Shah A, Perel P, et al. Prognostic models for stable coronary artery disease based on electronic health record cohort of 102 023 patients. Eur Heart J. 2014;35(13):844-52. doi:10.1093/eurheartj/eht533.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Толпыгина С.Н, Марцевич С.Ю., Гофман Е.А. и др. Опыт создания регистра для оценки исходов хронически протекающей ишемической болезни сердца: исследование “ПРОГНОЗ ИБС” Кардиоваскулярная терапия и профилактика. 2013;12(1):32-9. doi:10.15829/1728-8800-2013-1-32-39.</mixed-citation><mixed-citation xml:lang="en">Tolpygina SN, Martsevich SYu, Gofman EA, et al. Developing a register of outcomes of chronic coronary heart disease: CHD PROGNOSIS Study. Cardiovascular Therapy and Prevention. 2013;12(1):32-9. (In Russ.) doi:10.15829/1728-8800-2013-1-32-39.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Hammermeister KE, DeRouen TA, Dodge HT. Variables predictive of survival in patients with coronary disease. Selection by univariate and multivariate analyses from the clinical, electrocardiographic, exercise, arteriographic, and quantitative angiographic evaluations. Circulation. 1979;59(3):421-30. doi:10.1161/01.cir.59.3.421.</mixed-citation><mixed-citation xml:lang="en">Hammermeister KE, DeRouen TA, Dodge HT. Variables predictive of survival in patients with coronary disease. Selection by univariate and multivariate analyses from the clinical, electrocardiographic, exercise, arteriographic, and quantitative angiographic evaluations. Circulation. 1979;59(3):421-30. doi:10.1161/01.cir.59.3.421.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Свистунов А.А., Головачева Т.В., Скворцов К.Ю. и др. Частота сердечных сокращений как фактор риска развития сердечно-сосудистых заболеваний. Артериальная гипертензия. 2008;14(4):324-31. doi:10.18705/1607-419X-2008-14-4-324-331.</mixed-citation><mixed-citation xml:lang="en">Svistunov AA, Golovacheva TV, Skvortsov KYu, et al. Heart Rate as A Risk Factor for Development of Cardiovascular Diseases. A Review. Arterial Hypertension. 2008;14(4):324-31. (In Russ.) doi:10.18705/1607-419X-2008-14-4-324-331.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Ferrari R. A step further with ivabradine: SIGNIfY (Study assessInG the morbidity-mortality beNefits of the If inhibitor ivabradine in patients with coronarY artery disease) Eur Heart J. 2009;11:19-27. doi:10.1093/eurheartj/sup014.</mixed-citation><mixed-citation xml:lang="en">Ferrari R. A step further with ivabradine: SIGNIfY (Study assessInG the morbidity-mortality beNefits of the If inhibitor ivabradine in patients with coronarY artery disease) Eur Heart J. 2009;11:19-27. doi:10.1093/eurheartj/sup014.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Wood DA. EUROASPIRE I and II Group; European Action on Secondary Prevention by Intervention to Reduce Events. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events. Lancet. 2001;(357)9261:995-1001. doi:10.1016/s0140-6736(00)04235-5.</mixed-citation><mixed-citation xml:lang="en">Wood DA. EUROASPIRE I and II Group; European Action on Secondary Prevention by Intervention to Reduce Events. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events. Lancet. 2001;(357)9261:995-1001. doi:10.1016/s0140-6736(00)04235-5.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Карпова Н.Ю., Ра - шид М. А., Чипигина Н. С. и др. Кальцинированный аортальный стеноз: известные факты и перспективные исследования. Клиницист. 2020;14(1-2):34-41. doi:10.17650/1818‑8338‑2020‑14‑1-2‑34‑41.</mixed-citation><mixed-citation xml:lang="en">Karpova NYu, Rashid MA, Kazakova TV, et al. Calcific aortic stenosis: known facts and promising studies. Klinitsist (The Clinician). 2020;14(1-2):34-41. (In Russ.) doi:10.17650/1818‑8338‑2020‑14‑1-2‑34‑41.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Charlson ME, Pompei P, Ales HL. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;(40)5:373-83. doi:10.1016/0021-9681(87)90171-8.</mixed-citation><mixed-citation xml:lang="en">Charlson ME, Pompei P, Ales HL. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;(40)5:373-83. doi:10.1016/0021-9681(87)90171-8.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Толпыгина С. Н., Марцевич С.Ю. Стратификация риска сердечно-сосудистых осложнений при стабильной ишемической болезни сердца на основании прогностических индексов, шкал и моделей. Кардиоваскулярная терапия и профилактика. 2020;19(3):2528. doi:10.15829/1728-8800-2020-2528.</mixed-citation><mixed-citation xml:lang="en">Tolpygina SN, Martsevich SYu. Cardiovascular risk stratification in stable coronary artery disease based on prognostic scores and models. Cardiovascular Therapy and Prevention. 2020;19(3):2528. (In Russ.) doi:10.15829/1728-8800-2020-2528.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Pocock S, Bueno H, Licour M, et al. Predictors of one-year mortality at hospital discharge after acute coronary syndromes: A new risk score from the EPICOR (long-tErm follow uP of antithrombotic management patterns In acute CORonary syndrome patients) study. Eur Heart J: Acute Cardiovasc. Care. 2015:4(6):509-17. doi:10.1177/2048872614554198.</mixed-citation><mixed-citation xml:lang="en">Pocock S, Bueno H, Licour M, et al. Predictors of one-year mortality at hospital discharge after acute coronary syndromes: A new risk score from the EPICOR (long-tErm follow uP of antithrombotic management patterns In acute CORonary syndrome patients) study. Eur Heart J: Acute Cardiovasc. Care. 2015:4(6):509-17. doi:10.1177/2048872614554198.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
